AngioDynamics, Inc. ANGO
15.49
0.21
1.37%
as of 25 Sep
- Market cap
- $631.6M
- P/E
- 0.0×
Follow ANGO
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Aug '25 | Nov '25 | Feb '26 | May '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.43 | 1.75 | 1.51 | 1.42 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(27.06) | 115.60 | (151.94) | 25.96 | |
P/B ratio |
2.41 | 3.06 | 2.73 | 2.65 | |
Price to Tangible BV |
3.90 | 4.92 | 4.38 | 4.37 | |
EV/Sales |
1.49 | 1.80 | 1.56 | 1.42 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(57.35) | (98.55) | 110.06 | 146.97 | |
EV/FCF |
(28.49) | (42.07) | (214.05) | (138.33) | |
Quick Ratio |
1.19 | 1.20 | 1.26 | 1.37 | |
Current Ratio |
2.29 | 2.24 | 2.35 | 2.19 | |
Net Debt/EBITDA |
8.36 | 110.15 | 5.14 | 11.71 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.08 | 1.10 | 1.15 | 1.17 | |
Operating CF/Net income |
1.46 | (0.73) | 0.38 | (1.53) | |
Capex/Depreciation |
(0.12) | (0.07) | (0.18) | (0.07) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
8.48% | 9.78% | 9.03% | 9.44% | |
Selling, General and Administrative Expense of Revenue |
53.74% | 46.41% | 48.65% | 47.79% | |
Intangible Assets out of Total Assets |
0.26 | 0.25 | 0.25 | 0.25 | |
Share Based Compensation of Revenue |
5.90% | 3.64% | 3.42% | 4.52% | |
Graham Net Nets |
0.16 | 0.13 | 0.14 | 0.15 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.46%) | (5.17%) | (6.60%) | (7.97%) | |
Free Cash Flow Yield |
(3.64%) | (2.43%) | (0.48%) | (0.72%) | |
Revenue per Share |
1.84 | 1.91 | 1.89 | 2.09 | |
Operating CF per Share |
(0.39) | 0.11 | (0.07) | 0.42 | |
Capex per Share |
(0.02) | (0.01) | (0.02) | (0.01) | |
Free Cash Flow per Share |
(0.40) | 0.10 | (0.10) | 0.41 | |
Cash per Share |
0.94 | 1.00 | 0.91 | 1.30 | |
Shareholders Equity per Share |
4.34 | 4.24 | 4.17 | 4.11 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.34 | 4.24 | 4.17 | 4.11 | |
Free Cash Flow |
(16.64) | 4.24 | (4.12) | 17.04 | |
Working Capital |
88.37 | 89.39 | 89.49 | 88.68 | |
Capital Expenditures |
(0.73) | (0.42) | (1.01) | (0.41) | |
Net Current Asset Value |
69.87 | 68.00 | 68.23 | 67.06 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.00 | |
Net Profit Margin |
(14.40%) | (7.99%) | (10.31%) | (13.17%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
41.10 | 43.80 | 47.26 | 45.61 | |
Average Payables |
31.58 | 35.07 | 29.69 | 32.40 | |
Average Inventory |
63.48 | 65.74 | 60.84 | 57.22 | |
Average Assets |
279.64 | 280.62 | 273.05 | 273.65 | |
Average Common Equity |
187.72 | 181.55 | 179.61 | 176.90 |
Columns are period end dates